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Abstract This article focuses on squamous cell carcinomas
of the larynx, pharynx and oral cavity which count nearly 90%
of the head and neck squamous cell carcinomas (HNSCC).
Individual susceptibility depends on an individually given
genetic background and/or acquired conditions or factors
elevating the risk of HNSCC including smoking, alcohol
abuse, and improper oral hygiene. A key issue in HNSCC
pathogenesis is their development within large preneoplastic
fields of mucosal epithelium made up of genetically altered
cells that are clonally related to the carcinoma. Other
individual differences in development of HNSCC comprise
infection with pathogenic microbes and oncogenic human
papillomavirus (HPV) subtypes like HPV 16 (a strong risk
factor mainly for oropharyngeal cancer). Interestingly, the
presence of HPV 16 also goes in line with better outcome after
therapy. Vaccination against HPV infection in children plays
an increasing role in prevention strategies and probably also
reduces the oncogenic risk for HNSCC.
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Introduction
Cancer of the head and neck covers a brought spectrum of
different entities located in the upper digestive and
respiratory tract. The organs addressed are larynx, pharynx
(including naso-, oro- and hypopharynx), the oral cavity,
scull base, thyroids and the salivary glands. This article
focuses on squamous cell carcinomas of the larynx,
pharynx and oral cavity which cover the majority of nearly
90% of the head and neck carcinomas (HNSCC).
The individual susceptibility to develop a HNSCC
depends not only on the genetic background of the
patient but mostly is triggered by a number of factors
contributing to an impaired health status of the epithelia
in the oral cavity but the pharynx and the larynx as well.
Smoking and alcohol consumption are main factors
damaging the normal physiology of squamous epithelia
and their function and therefore are the main factors for
the development of HNSCC. It was shown by numerous
authors (e.g. [1, 2]) that risk for HNSCC is directly
correlated with duration of smoking and number of
cigarettes smoked, and considerably increased in individ-
uals consuming more than 50 g of alcohol per day. Of
particular interest is the synergism of both risk factors and
the observation that the number of pack years (number of
years smoking multiplied with the mean number of
cigarettes per day divided by 20, the usual pack size) best
correlates e.g. with an increasing risk for development of
laryngeal HNSCC [1, 2] seemingly independent from the
actual time period of smoking.
It is well known, that persistence of any irritation and
inflammation increases the risk of cancer. The irritating and
pro-inflammatory effects of tobacco smoke as well as those
of higher concentrated alcohol and other irritants like those
of chemical irritants or esophageal reflux not only trigger
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inflammation but also interfere with a proper voice and
cause dysfunction of the epithelia e.g. of the vocal chords
and lead to lesions and increased need for proliferation and
repair.
In addition to tobacco smoke and alcohol abuse,
other factors are able to increase the risk for HNSCC
and thus should be prevented. These life-style related
factors include improper hygiene like reduced numbers
of tooth brushes but also high-frequent use of aggres-
sive fluids for mouthwashes and gargling can disturb
the normal mouth flora and do harm to the epithelia.
This reduces their barrier function and, hence, makes
them more vulnerable for infection with pathogens.
However, the need to replace damaged cells and to
repair small mucosal lesions contributes to an increased
vulnerability due to the need for higher mitosis rate and
proliferation, which increase the general risk for genetic
instability and accumulation of somatic mutations. The
latter leads to hyperplasia and, later on, often further to
the development of leukoplakia, preneoplastic fields of
mucosal epithelium called SIN (squamous intraepithelial
neoplasia) and their progression from stage SIN I over
SIN II to SIN III.
The development of SIN III (which reflects the earliest
stage of detectable breakthrough of the malignant cells
through the basal membrane) is the key issue in HNSCC
pathogenesis. HNSCC commonly develop within large
preneoplastic fields of SIN I to III which are made up
of genetically altered cells that are clonally related to the
carcinoma. These preneoplastic fields often extend into
the surgical margins when tumours are excised, and can
cause local recurrences and second primary tumours [3,
4]. In the recent years more knowledge about individual
biologic factors of the given tumour and the individual
patient, suffering from the tumour has been generated. Not
only the physician treating the disease but also the whole
scientific community which is concerned with head and
neck cancer has to face more to implicated multimodality
treatment options for HNSCC also suggested as alterna-
tive treatment to surgery even in resectable disease. In
many cases, selecting the right treatment is difficult due to
the lack of valid predictive markers to achieve some
information on the individual response to the single
treatment option. Regarding chemo radiation, difficulties
such as early and late toxicities [5, 6], reduced functional
outcome, and treatment failure leading to high risk
salvage surgery with severe complications in many cases
have to be managed. To address this problem, Lefebvre
and Ang [7] worked out a list of guidelines for better
outcome-specification after organ preservation chemo
radiation, which should be used in future clinical trials.
These recommendations defined a new endpoint: laryngo-
esophageal dysfunction-free survival. Also considering
better response (i.e. results), future trial populations
should include patients with limited tumour size like T2
or T3 laryngeal or hypopharyngeal squamous cell carci-
noma taking into account additional specific factors.
Following the recommendations of Lefebvre and Ang
[7], biomarker studies including excision repair cross-
complementary-1 gene, E-cadherin, beta-catenin, epiregu-
lin, amphiregulin, and p53 mutation should be favoured
aiming at the enthusiastic goal of finding hints for
individual treatment recommendations. Furthermore, che-
mo resistance of tumour cells in general can be provoked
by mutations in oncogenes (e.g., K-ras), loss of tumour
suppressors (e.g., p53, p16INK4a) or dysregulation of
genes involved in cell cycle control, cell proliferation,
signal transduction, angiogenesis or apoptosis [8]. Focus-
ing on the update discussion of molecular biological
relevance in HNSCC by Leemans and colleagues, limit-
less replicative potential of head and neck cancer cells is
caused by abrogation of the p53 and retinoblastoma (RB)
pathways that perturb cell cycle regulation, probably in
the context of telomerase reverse transcriptase (TERT)
expression and under influence of the expressed HPV 16
proteins E6 and E7 [3]. A subgroup of HNSCCs becomes
independent from growth factors owing to somatic
changes in the epidermal growth factor receptor (EGFR)
signalling pathway. HNSCC escape from the growth
inhibitory transforming growth factor-β (TGFβ) pathway
by somatic mutation or chromosomal loss of key genes.
This pathway seems to be interconnected to the nuclear
factor-κB (NF-κB) pathway. Furthermore, the PI3K–
PTEN–AKT pathway is frequently activated in HNSCC,
wherefore it might be a target in new specific treatment
strategies [3].
Unfortunately in HNSCC, all these biomarkers showed
vague correlation with better outcome after chemo radia-
tion, but suffer from strongly discriminating results, many
technical peculiarities, and in particular from investigations
being addressed only in highly selected artificial surrogates
for real tumours, namely cell lines; thus the clinical
relevance is still limited (except regarding p16INK4a and
HPV 16 in oropharyngeal cancer) [9] and so far are not
suitable for individualised or personalised decision making.
Past and current literature in translational research focuses
mainly on laryngeal and, since HPV 16 came up, in
particular on oropharyngeal HNSCC.
Regarding prevention strategies and as well the move
towards personalised medicine in head and neck oncology,
this article will give some ideas about the different
individual factors of susceptibility, genetic alterations due
to mutagens and virus infections, and discuss new methods
of ex vivo performed pre-treatment response evaluation,
which could be taken into account for future decision
making.
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Environmental risk factors
The main risk factors for HNSCC are the lifestyle factors
tobacco smoking and alcohol consumption [1], while there
are also occupational substances like asbestos, polycyclic
aromatic hydrocarbons, dust and solvents, promoting the
development of HNSCC [2, 10, 11]. There is some
evidence for an influence of genetic factors, as people with
a family history of head and neck cancer were shown to
have an increased risk of developing laryngeal cancer [12].
Despite this knowledge, it is not well known up to which
extent survival time after diagnosis of laryngeal cancer is
influenced by the above mentioned factors [13]. Cancer risk
is directly correlated with duration of smoking and
number of cigarettes smoked, and considerably increased
in individuals consuming more than 50 g of alcohol per
day. Tobacco smoke contains many carcinogens includ-
ing a group of N-nitrosamines that produce carcinogenic
methyl and pyridyloxobutyl DNA adducts [14]. A further
constituent of tobacco smoke is the highly toxic acetalde-
hyde that produces genotoxic 1,N2-propano-20-deoxygua-
nosine DNA adducts. Acetaldehyde is also an intermediate
product of ethanol metabolism and its concentration
increases in a multiplicative manner in individuals who
are simultaneously smoking and drinking alcohol [14].
This observation might explain the synergistic and
multiplicative effect found for alcohol and smoking in
laryngeal cancer risk and augments the important aspect of
confounding by tobacco and alcohol in HNSCC epidemi-
ologic research [2].
Genetic factors of individual susceptibility
Individual defence against mutagens
Obviously, the upper mentioned exogenous risk factors
alone cannot, however, completely explain all cases of
HNSCC. Therefore, many studies have been conducted
to identify biomarkers that reflect host susceptibility
more closely. Those that have been found include
variations in carcinogen metabolism, DNA adduct
formation and DNA repair activity [15]. The specific
influences of these markers have been established for
environmentally induced cancers such as lung tumours
and HNSCC [16]. An important reaction in DNA repair
pathways is poly(ADP-ribosyl)ation, which is induced by
the presence of DNA single-strand breaks [15]. DNA
damage associated with oxidative stress activates DNA
repair pathways that involve various enzymes, including
poly (ADP-ribose) polymerase (PARP) [17]. PARP is a
highly conserved, ubiquitous nuclear enzyme found in
most eukaryotic cells. Therefore, PARP activation is an
immediate cellular response to metabolic, chemical, or
radiation-induced DNA single strand breaks, reflecting
the main mutational mechanism in development of
HNSCC.
Several forms of cancer are more dependent on PARP
than regular cells, making PARP an attractive target for
chemotherapeutic cancer therapy. Therefore, a new group
of PARP-inhibitors has been developed and is under
clinical investigation in lung, prostate, colorectal and
breast/ovarian cancer. Some cancer cells that lack the
tumour suppressor PTEN may be sensitive to PARP. Hence
PARP inhibitors may be effective against many PTEN-
defective tumours (e.g. some aggressive prostate cancers
and assumable HNSCC) [8].
A unique and for detection of individual susceptibil-
ity very interesting property of PARP is that it is
inactive unless DNA single strand breaks are present
[18]. Poly(ADP-ribose) undergoes degradation, which is
catalysed by poly(ADP-ribose) glycohydrolase [19]
resulting in rapid turnover of the polymer under con-
ditions of DNA breakage. Poly(ADP-ribosyl)ation plays
a major role in facilitating DNA base excision repair and
in maintaining the genomic stability of cells exposed to
genotoxic stress [16] and might have a significant impact
on the process of neoplastic transformation. This
assumption is based on findings that defective DNA
repair is associated with increased risks for cancer in
humans and that inter-individual differences in DNA
repair capacity are markers for individual susceptibility
to cancer [20].
We investigated whether differences in the activity of
PARP are associated with the risk for laryngeal cancer
within the so called Rhein-Neckar-Larynx trial [15]. In this
case-control study on genetic, lifestyle and occupational
risk factors for laryngeal cancer, PARP activity was
assessed as DNA damage–induced poly(ADP-ribose) for-
mation in human peripheral blood lymphocytes. Polymer
formation was determined as the cellular response to
bleomycin, a well-known inducer of DNA strand breaks,
in lymphocytes from 69 laryngeal cancer patients and 125
healthy controls. The frequency of bleomycin-induced
polymer formation, measured as mean pixel intensity, was
significantly lower in cases (74.6, SE=3.7) than in controls
(94.5, SE=3.5), and was not influenced by smoking, age or
sex. There was no significant difference between cases
(59.1, SE=5.2) and controls (50.5, SE=3.7) in basal
polymer formation (in cells not treated with bleomycin).
When the upper tertile of polymer formation was used as
the reference, the odds ratio for the lower tertile of
bleomycin induced polymer formation was 3.79 (95%
confidence interval = 95% CI: 1.37–10.47, p=0.01).
Peripheral blood lymphocytes from laryngeal cancer
patients thus showed significantly less bleomycin-induced
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poly(ADP-ribose) formation. These results suggest that a
reduced PARP activity might be associated with an
increased risk for laryngeal cancer.
There are more than 150 human DNA repair genes other
than PARP known [21]. These can be sub-grouped into
genes associated with DNA damage signalling and regula-
tion of the repair system genes and genes working with
distinct repair pathways such as mismatch repair, base
excision repair, nucleotide excision repair (NER), direct
damage reversal, and DNA double-strand break repair.
NER is the main pathway for removing the bulky DNA
adducts caused by the chemical mutagens present in
tobacco smoke and alcohol. There are about 30 proteins
involved in NER [22]. NER consists of two sub-pathways,
namely the global genome repair (GGR) that repairs
anywhere in the genome, and the transcription coupled
repair (TCR) involved in damage repair at actively tran-
scribing sites. The complex interaction of the NER proteins
in the pathway is not yet completely known, but damage
recognition is specific for each of these sub-pathways (more
details in [21]). As already mentioned, laryngeal cancer is
known to be associated with smoking and high alcohol
consumption. Nucleotide excision repair (NER) plays a key
role in repairing DNA damage induced by these exposures,
and hence might affect laryngeal cancer susceptibility. In
the upper mentioned Rhein-Neckar-Larynx trial that in-
cluded 248 cases and 647 controls, the association of
laryngeal cancer with 14 single nucleotide polymorphisms
(SNPs) in eight NER genes (XPC, XPA, ERCC1, ERCC2,
ERCC4, ERCC5, ERCC6, and RAD23B) was analysed
with respect to smoking and alcohol exposure. Data were
stratified for age and gender, and adjusted for smoking,
alcohol consumption and education. Pro-carriers of ERCC6
Arg1230Pro showed a decreased risk for laryngeal cancer
(OR 5 0.53, 95% CI: 0.34–0.85), strongest in heavy
smokers and high alcohol consumers. ERCC5 Asp1104His
was associated with risk in heavy smokers (OR 5 1.70, 95%
CI: 1.1–2.5). Val-carriers of RAD23B Ala249Val had an
increased cancer risk in heavy smokers (OR 5 1.6, 95% CI:
1.1–2.5) and high alcohol consumers (OR 5 2.0, 95% CI:
1.1–3.4). The combined effect of smoking and alcohol
intake affected risk, at high exposure level, for ERCC6
1230Pro carriers (OR 5 0.47, 95% CI: 0.22–0.98) and
RAD23B 249Val carriers (OR 5 2.6, 95% CI: 1.3–4.9).
When tested for gene–gene interaction, presence of three
risk alleles in the XPC-RAD23B complex increased the risk
2.1-fold [21].
The data strengthen the evidence that common genetic
variations in NER genes can significantly modify HNSCC
risk. However, until now it is not yet completely clear if
this knowledge might add to prevention strategies or even
decision-making regarding selection of optimised multi-
modal treatment regimens.
So far it has to be summarised, that only little numbers
of investigations in the field of genetic susceptibility
suggest existence of defined inter-individual differences
in genetic defence against mutagens in patients which
could be considered to be useful for further additional
personalisation of treatment strategies for an individual
HNSCC.
Differences in detoxification of hazardous substances
Some previous studies give important hints to genetic
polymorphisms in alcohol dehydrogenases (ADH) as risk
modifiers for head and neck cancer. ADH1B and ADH1C
(previously called ADH2 and ADH3 respectively) are
responsible for the metabolism of ethanol to acetaldehyde,
which is classified as potentially carcinogenic to humans
[23]. Higher ethanol oxidation activity has been associated
with the ADH1B_2 allele however, a 6.6- fold increased
risk of head and neck cancer has been observed in
homozygous carriers of the ADH1B_1 allele among
Japanese alcoholics [24]. In the case of ADH1C, the
presence of the _1 allele results in a higher activity in
alcohol metabolism capacity and formation of acetalde-
hyde than the _2 allele. Thus, ADH1C_1 has been
implicated as a risk factor for laryngeal tumours. Indeed,
this was shown in one small study on 39 alcoholic men
with upper aerodigestive tract cancer, including 18 with
laryngeal tumours, compared to 37 alcoholic male con-
trols, but so far was not confirmed in other studies
investigating head and neck cancers risk in Caucasians
[14]. As reported in an abstract, a German study showed
an increased risk of ADH1C_1 carriers for tumours of the
upper alimentary tract, as well as higher salivary acetal-
dehyde concentrations in volunteers with the ADH1C_1_1
genotype [14].
Glutathione-S-transferases (GST) M1 and T1 are
involved in the detoxification of tobacco carcinogens –
previous studies concerning the relevance of the highly
prevalent homozygous deletion of the genes (GSTM1
null or GSTT1 null, respectively) to risk of head and
neck cancer have yielded inconsistent results. The data of
the Rhein-Neckar-Larynx trial revealed no significance
regarding the specific enzyme polymorphisms in
HNSCC. Neither the putative risk genotypes ADH1B_
2/_1 (OR 0.86, 95% CI: 0.41–1.82) or ADH1C_1/_1
(OR 1.06, 95% CI: 0.7–1.62) nor GSTM1 null (OR 0.94,
95% CI: 0.62–1.42) or GSTT1 null (OR 1.34, 95% CI:
0.74–2.42) were associated with an overall increased risk
for laryngeal cancer even in stratified analysis [14]. The
lack of risk modification by the studied genotypes
emphasises the ethnic differences between Caucasians
and the Asian (Japan) population and points to ethnic
different patterns of HNSCC susceptibility.
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HPV 16 as risk and predictive factor for oropharyngeal
cancer
Growing relevance has been demonstrated for the impact of
infection with oncogenic subtypes of the human papilloma
virus (HPV), and in particular presence of HPV 16 in and
its influence on development of HNSCC. Although HPV
16 alone accounts for more than 90% of cases of HPV-
positive squamous-cell carcinomas of the oropharynx, a
more accurate and probably higher proportion might be
found by testing for other types of HPV (e.g., types 18, 31,
33, and 35), which are infrequently detected in oropharyn-
geal cancers. Genomic DNA of oncogenic HPV is detected
in approximately 26% of all squamous-cell carcinomas of
the head and neck worldwide but the molecular evidence is
most rigorous and consistent for oropharyngeal squamous-
cell carcinoma, in which viral integration and the expres-
sion of viral oncogenes (E6 and E7) have been shown [25].
The example of the relationship between HPV and cervical
cancer [26] indicates that high-risk sexual behaviour will
increase the risk of other cancers caused by HPV [27]. In
the remarkable report by D´Souza could be demonstrated
that sexual behavior (oral sex, high lifetime numbers of
sex-partners) correlates with a higher incidence of oral HPV
16 infection. Furthermore, HPV 16 presence correlates
significantly with elevated risks of oropharyngeal cancer
independent to degree of tobacco and alcohol abuse [27].
Several retrospective case series have shown that among
patients with oropharyngeal HNSCC, patients with HPV-
positive tumours have a better prognosis than patients with
HPV-negative tumours [25]. The recently published retro-
spective study of the RTOG provides strong evidence that
tumour HPV status is an independent prognostic factor for
overall survival and progression-free survival among
patients with oropharyngeal squamous-cell carcinomas,
which is consistent with the hypothesis that HPV-positive
and HPV-negative oropharyngeal squamous-cell carcino-
mas are distinct and have different causes, risk-factor
profiles [28] and survival outcomes. Ang and co-authors
could demonstrate clearly, that patients suffering from
oropharyngeal carcinoma with negative HPV 16 stage and
high tobacco intake are at highest risk compared to the
group of HPV 16-positive, non smoking patients [29]. Due
to this overwhelming difference, the authors recommend to
separate HPV 16 associated tumours in future clinical trials.
Moreover, the existing data suggest that HPV 16 is a strong
marker which could be used and should lead to differen-
tiated treatment strategies due to better radio- and chemo
response in the HPV 16-positive group. Whether patients
with HPV-positive tumours who are considered to be in the
low-risk category can be spared the long-term complica-
tions of intensive, multimodal therapy without compromis-
ing their survival is now a highly relevant clinical question
[28]. So HPV 16 is a new marker for personalised treatment
concepts in HNSCC.
Vaccination against oncogenic HPV subtypes
as appropriate predictive action
Two vaccines are available for vaccination against the two
high-risk HPV subtypes 16 and 18: Gardasil (developed by
Merck Sharp & Dohme Ltd. and Sanofi Pasteur in
collaboration with the German Cancer Research Center
[DKFZ] in Heidelberg), and Cervarix (GlaxoSmithKline).
Gardasil contains genetically engineered capsid proteins of
HPV 16 and 18 and also of the low-risk subtypes 6 and 11,
which are absent in Cervarix. Gardasil is approved for
vaccination in the EU since 2006 for vaccination of females
(age 9–26) and boys (age 9–15). Cervarix is a bivalent
recombinant vaccine for the prevention of cervical pre-
cancers and cervical cancer associated with HPV 16 and
HPV 18 only approved by the EMEA (in 2007) and FDA
(in 2009) for use in girls and young women (aged 10–25).
Regarding vaccination efficacy, the view so far was focused
on cervix carcinoma [30]. Since both vaccines have
efficacy against, and disease contribution of, HPV 16,
HPV 18, but also other oncogenic HPV types not included
in the vaccine (e.g. HPV 31), their use might allow for a
reduction of HPV-induced cancers not only of the cervix.
However, vaccination of girls and young females and also
of boys against the oncogenic HPV subtypes might not
only add to prevention of this malignancy by prevention of
transmission of HPV as causative agents of cervix cancer
but also of other cancer including HNSCC [30–32].
Markers for individual response evaluation
Despite ASCO in 2004 admonished from assay based
therapy in general outside of clinical trials [33], the field of
clonogenic and colony-formation assays for chemosensi-
tivity testing developed encouraging new directions in
various tumour entities. Individual response evaluation for
better biology-based decision making is more desirable than
ever since various competitive therapy strategies even in
case of resectable HNSCC (i.e. advanced laryngeal and
hypopharyngeal cancer) are increasingly promoted, and
many new substances, antibodies, and small molecules
come into the clinical view. Especially in multimodality
treatment in current clinical trials aiming on inclusion of
pharmaceuticals with non-overlapping toxicity profiles and
hence trying to execute treatment with escalating doses to
fathom out the limits of maximum tolerable treatment
regimes for selected patients with good general state of
health we have to face dramatically increased early and late
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toxicities, which require more robust pre-treatment criteria
to select responders (and non-responders for definitive
surgical treatment). For HNSCC, assay-based individual
testing was inflicted with a series of technical problems and
principal questions like micro heterogeneity, flavin-induced
cell toxicity, chaotropism due to photoreactivity of pharma-
ceuticals and presence of UV and other short-wavelength
light, lack of differentiation between tumour and stromal
cells, differences in chemosensitivity of tumour and stromal
cells, structural needs for specific handling of the testing,
lack of specific dose related sensitivity towards single and
combined substances etc., but these issues have been
addressed in recent publications (Overview in [34]).
Currently, we emphasise the advantages of the FLAVINO-
assay for clinical research, which considers the above
mentioned major pitfalls in assay-based diagnosis before
starting the therapy. Unfortunately, this test requires a
strong definitive hospital setting with a closed relation
between the surgical and the laboratory units and perfor-
mance under flavin-protecting conditions in a “same day”
procedure. Besides further evaluation of definitive clinical
introduction of assay-based guidance in decision-making
for therapy additional, translational genetic and molecular
biologic response marker research could be strongly pushed
forward by correlating these results with the outcome in ex-
vivo chemosensitivity testing of the individual tumour [35].
Figs. 1 and 2 show the correlation of response of the
patient’s tumour in vivo to one single cycle of induction
chemotherapy with TPF (docetaxel, cisplatin, 5-fluorouracil) +
cetuximab and the reduction of colony formation in the
FLAVINO-assay in response to maximum tolerable plasma
concentrations of the pharmaceuticals [36, 37].
It is mandatory that ex-vivo chemosensitivity testing in
all settings of clonogenic and colony-formation assays
should include all different cell types within a given tumour
and being able to test these cells separately. Furthermore,
detailed information about combination efficacy of different
drugs and radiation therapy for the given tumour has to be
addressed. In this respect, the FLAVINO-Assay indeed
allows for a detailed analysis of colony formation by
epithelial and stromal cells under exposure to either
cisplatin or docetaxel and combined exposure to both. We
think that ex-vivo chemosensitivity testing in HNSCC has
reached a mature technical level and is feasible for use
within clinical trials.
We go in line with the ASCO recommendation in 2004
[33] that chemosensitivity testing should not be used
uncritically without selection of the right method outside
of clinical trials. All clonogenic test systems which were
propagated before 2004 failed to show suitability for proper
chemo-sensitivity testing of HNSCC due to a number of
reasons. Most relevant is the lack of flavin-protecting
conditions, lack of separation between the different cell
types, and mainly measurement only of sum signals which
in general do not allow for more distinguished chemo
recommendations. But, regarding personalised medicine as
labelled by ASCO in 2009, test systems for HNSCC are
promising since they have become more reproducible and
differentiated in the recent years. The authors, for instance,
obtained very promising results in the FLAVINO-assay
[35]. These data underline that even in organ preservation
treatment in advanced laryngeal cancer, predictive assays
for better decision making in balancing competing therapy
options is strongly needed since many patients still do not
respond to multimodality treatment and have to go through
salvage surgery procedures with high complication rates
and severe late toxicity events, reducing significantly
quality of life. In non responders, definitive surgery is the
best treatment and should be favoured by enthusiastic
research in more specific biology based pre-treatment
diagnostics.
Chemosensitivity testing using the FLAVINO-assay
could be an option for that and should be included into
future clinical trials. A close and confiding cooperation
with the pathologist is mandatory because of test material
has to be fresh, unfixed, and must be quickly handled under
flavin-protecting conditions. Furthermore, the FLAVINO-
assay can be recommended for pharmacological ex-vivo
characterisation of new substances potentially useful in
treatment of HNSCC, proposing more realistic results
Fig. 1 Image series of a
71 years old male patient
suffering from a laryngeal
cT4acN2bcM0 carcinoma (left)
pre and intra therapy after
receiving one cycle TPF +
cetuximab (right); the patient
was early evaluated as good
responder
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compared to animal models or established cell lines
which are almost not representative for the average
HNSCC. In this context, new developments like the
TSC assay (tissue slice culture assay) [38] showed to be
very promising since the architecture of the tissue can be
preserved in culture. This method was first performed in
brain tissue for investigation of pharmacological effects ex
vivo. By use of living slices of 300 μm thickness obtained
from brain resections of four patients with pharmacor-
esistant temporal-lobe epilepsy, cell death was induced by
tumour-necrosis-factor-related apoptosis-inducing ligand
(TRAIL) [38]. Remarkably, this TRAIL-induced cell death
revealed an important species difference between man and
mouse which are widely used for preclinical studies:
TRAIL did not damage murine brain cells. An important
consequence of this finding was the definitive stop of
further clinical phase-I trials with TRAIL to avoid fatal
brain damage in patients. In future, development of this
TSC-assay into ex-vivo testing of HNSCC and combining
this approach with integration of the methodological
advantages of the FLAVINO-assay could be an important
advancement.
Conclusions and outlook
Personalised medicine becomes also relevant in decision
making for treatment in HNSCC. Current therapy options
in daily routine are driven by personal experience and a
small number of clinical randomised trials, overestimating
the impact of chemo radiation due to the lack of well
planned and conducted surgical trials. Future clinical trials
should pay more attention to the individual biology/ genetic
background of the patient and the tumour including its
vulnerability due to genetic susceptibility and life-style
factors, presence of HPV 16 infection and other possible
biomarkers so far not validated. These factors should not
abandon the possible advantages of pre-treatment response-
evaluation using the newly improved short term culture
assays. Due to the fact that overall survival of patients
suffering from HNSCC is still only 42% in Europe [39] and
many of them underwent average treatment, which might
be wrong for the single patients, there is still a lot of work
to do in better canalising personalised concepts.
However, the better alternative to treatment in general
should be prevention of the disease. The best prevention
strategy for HNSCC is complete avoidance of exposure to
tobacco smoke during the whole life time and also
reduction of harm for the epithelia by avoidance of other
self-induced exposure to irritating and mutagenic life style-
associated risk factors like alcohol and alcohol abuse.
Further lowering of environmental and occupational expo-
sure to irritating compounds and other groups of chemicals
with mutagenic and immunomodulatory properties on the
one side and proper oral hygiene and regular physical
examination of the oral cavity by a dentist on the other side are
also preventive against HNSCC or (referring to the latter)
allows for early detection of precancerous lesions. In addition,
vaccination against HPVappears to be a very attractive way to
reduce the risk for HNSCC.
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Fig. 2 Comparison of IC50 concentrations (inhibitory concentration
which diminish colony formation to 50%) in the FLAVINO assay [35]
of HNSCC with lower response to TPF-IC with good responders. (a),
(b): based on volume reduction <50% (left) vs. >50% (right); (c), (d):
based on tumour-surface reduction <30% vs. (left) vs. >30% (right).
Horizontal lines in a, c and b, d, represent maximum tolerable plasma
levels of cisplatin (6,667 nM [36]) and docetaxel (550 nM [37]),
respectively. Clear differences in IC50 for P and T exist between
responders and no responders, and these allow for their distinction and
hence could build a rational to analyse chemo response before starting
chemotherapy
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